Skip to main content

Complications aiguës des vascularites associées aux ANCA

  • Chapter
Maladies rares en médecine d’urgence

Part of the book series: Références en médecine d’urgence. Collection de la SFMU ((REFERMED))

  • 1176 Accesses

Résumé

Les vascularites associées aux anticorps anti-cytoplasme (ANCA) de polynucléaires neutrophiles (AAV) sont des vascularites intéressant de façon prédominante les vaisseaux de petits calibres et comprennent la granulomatose avec polyangéite (GPA), anciennement dénommée granulomatose de Wegener, la polyangéite microscopique (PAM) et le syndrome de Churg et Strauss (SCS) dont le nom sera très prochainement modifié pour « granulomatose éosinophilique avec polyangéite ». Les dates clés dans l’histoire des AAV sont: la première description de la GPA par Friedrich Wegener en 1936, la première description de la PAM en 1948 et la description des ANCA en 1982.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Hoffman GS, Kerr GS, Leavitt RY et al. (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488–98

    Article  PubMed  CAS  Google Scholar 

  2. Guillevin L, Cordier JF, Lhote F et al. (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40: 2187–98

    Article  PubMed  CAS  Google Scholar 

  3. Reinhold-Keller E, Beuge N, Latza U et al. (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43: 1021–32

    Article  PubMed  CAS  Google Scholar 

  4. Guillevin L, Durand-Gasselin B, Cevallos R et al. (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42: 421–30

    Article  PubMed  CAS  Google Scholar 

  5. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P (1999) Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78: 26–37

    Article  CAS  Google Scholar 

  6. Sablé-Fourtassou R, Cohen P, Mahr A et al. (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143: 632–8

    Article  PubMed  Google Scholar 

  7. van der Woude FJ (1985) Anticytoplasmic antibodies in Wegener’s granulomatosis. Lancet 2: 48

    PubMed  Google Scholar 

  8. Leavitt RY, Fauci AS, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33: 1101–7

    Article  PubMed  CAS  Google Scholar 

  9. Masi AT, Hunder GG, Lie JT et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094–100

    Article  PubMed  CAS  Google Scholar 

  10. Jennette JC, Falk RJ, Andrassy K et al. (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187–92

    Article  PubMed  CAS  Google Scholar 

  11. Pagnoux C, Mahr A, Hamidou MA et al. (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359: 2790–803

    Article  PubMed  CAS  Google Scholar 

  12. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120: 12–7

    Article  PubMed  CAS  Google Scholar 

  13. de Groot K, Harper L, Jayne DRW et al. (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150: 670–80

    Article  PubMed  Google Scholar 

  14. Stone JH, Merkel PA, Spiera R et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–32

    Article  PubMed  CAS  Google Scholar 

  15. Jones RB, Tervaert JWC, Hauser T et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–20

    Article  PubMed  CAS  Google Scholar 

  16. Jayne DRW, Gaskin G, Rasmussen N et al. (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180–8

    Article  PubMed  CAS  Google Scholar 

  17. Walsh M, Merkel PA, Mahr A, Jayne D (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) 62: 1166–73

    Article  Google Scholar 

  18. Hiemstra TF, Walsh M, Mahr A et al. (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304: 2381–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. Charles .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Charles, P., Puéchal, X. (2013). Complications aiguës des vascularites associées aux ANCA. In: Maladies rares en médecine d’urgence. Références en médecine d’urgence. Collection de la SFMU. Springer, Paris. https://doi.org/10.1007/978-2-8178-0350-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0350-0_9

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0349-4

  • Online ISBN: 978-2-8178-0350-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics